Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Coricidin HBP** is a brand line of over-the-counter combination medications designed for cold and flu symptom relief, particularly safe for individuals with high blood pressure as it contains no decongestants. Different formulations include **Coricidin HBP Cough & Cold** (chlorpheniramine maleate 4 mg as antihistamine + dextromethorphan hydrobromide 30 mg as cough suppressant), **Coricidin HBP Maximum Strength Multi-Symptom Flu** (acetaminophen 325-500 mg as pain reliever/fever reducer + chlorpheniramine maleate 2 mg + dextromethorphan HBr 10-15 mg), and others like Chest Congestion (dextromethorphan + guaifenesin). These act via analgesia (acetaminophen inhibits prostaglandin synthesis), H1 receptor antagonism (chlorpheniramine blocks histamine to reduce rhinorrhea/sneezing), antitussive suppression of cough reflex (dextromethorphan acts on sigma-1 receptors in the medulla), and expectoration (guaifenesin increases respiratory secretions). Originally introduced by Schering-Plough in 1949, now manufactured by Bayer HealthCare LLC, it provides temporary relief for cough, congestion, pain, fever, and runny nose in adults/children ≥12 years, taken orally every 4-6 hours with liver warnings due to acetaminophen.[1][2][4][5][7][8][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coricidin HBP.